Lenalidomide and Tafasitamab interaction
Lenalidomide and Tafasitamab: the Tafasitamab prescribing label flags this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.
Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.
What the FDA labels say
From the Tafasitamab (MONJUVI) label · effective 2026-02-02
The combination of MONJUVI with lenalidomide is contraindicated in pregnant women because lenalidomide can cause birth defects and death of the unborn child.
Refer to the lenalidomide prescribing information for dosage modifications.
MONJUVI is initially administered in combination with lenalidomide.
Refer to the lenalidomide prescribing information on use during pregnancy.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.